advanced gastric cancer


Also found in: Acronyms.

advanced gastric cancer

Invasive adenocarcinoma of the stomach which extends beyond the submucosa.

Clinical findings
Peptic ulcer symptoms, anaemia, weight loss, haematemesis and symptoms of gastric outlet obstruction.

Management
Palliative surgical resection, surgical bypass (gastrojejunostomy), radiation therapy and endoscopic techniques; radical gastrectomy carries a rate of perioperative morbidity and no survival benefit.
Mentioned in ?
References in periodicals archive ?
Overall survival rates for gastric cancer according to the depth of invasion in overall gastric cancer (A), early gastric cancer (B), and advanced gastric cancer (C).
Based on these favorable data, Genta recently initiated the TESEGAST study -- a multinational, randomized, placebo-controlled trial of tesetaxel as 2nd-line therapy for patients with advanced gastric cancer.
Experts at ASCO agreed that all patients with advanced gastric cancer should be tested for HER2, and if found to be positive should be treated with trastuzumab in addition to their usual chemotherapy.
This trial is expected to be a "run-in" study for a planned Phase 3 trial in previously untreated patients with advanced gastric cancer.
Tesetaxel has been designated an Orphan Drug by both FDA and EMA for treatment of patients with advanced gastric cancer.
24, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the termination of all Amgen-sponsored clinical studies of rilotumumab in advanced gastric cancer, including the Phase 3 RILOMET-1 and RILOMET-2 studies.
The results of the ToGA trial are promising and have already had an impact on the management of patients with HER2/ neu-positive advanced gastric cancer.
a novel oral anti-cancer agent, recently received Marketing Authorization from the EMA for the treatment of adults with advanced gastric cancer when given in combination with cisplatin (March 14, 2011), which will form the basis of its commercial entry into this region.
However, the prognosis for patients with locally advanced gastric cancer remains poor, even after potentially curative resection, with a high risk of locoregional and/or distant recurrence, which occurs in almost 60% of patients who undergo R0 resection [1-3].
a privately held biotechnology company based in San Francisco, California, today announced positive interim data from a Phase 2 trial of the Company's lead oral kinase inhibitor, Telatinib, for the first-line treatment of patients with advanced gastric cancer.
Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy in first-line HER2-positive advanced gastric cancer [abstract].
announced today that the European Commission (EC) has granted marketing authorization for Teysuno(TM) (S-1), a novel oral anti-cancer agent indicated for the treatment of adults with advanced gastric cancer when given in combination with cisplatin.

Full browser ?